Objective:To evaluate the efficacy and safety of Peitu Shengjin prescription versus H1 antihistamine in the treatment of allergic rhinitis.Methods:Electronic searching"China Knowledge Network","Wanfang ...Objective:To evaluate the efficacy and safety of Peitu Shengjin prescription versus H1 antihistamine in the treatment of allergic rhinitis.Methods:Electronic searching"China Knowledge Network","Wanfang Database","Vip Database","Chinese Biomedical Literature Database",PubMed,Embase,The Cochrane Library,all published on the prescription of Peitu Shengjin prescription comparison H1 antihistamine In randomized controlled trials(RCTs)of drug treatment of allergic rhinitis,two researchers screened the literature according to the inclusion and exclusion criteria,and conducted Meta-analysis using RevMan5.3 software.Results:A total of 22 studies were involved,involving a total of 1463 subjects,including 822 in the treatment group and 641 in the control group.Meta-analysis results show that compared with oral H1 antihistamines,Peitu Shengjin prescription can improve the total effective rate of allergic rhinitis(RR=1.19,95%CI[1.14,1.24],P<0.00001);reduce recurrence Rate(RR=0.46,95%CI[0.23,0.90],P=0.02);reduce serum IL-6(MD=-17.33,95%CI[-21.96,-12.70],P<0.00001)and serum IL-8(MD=-100.35,95%CI[-175.18,-25.52],P=0.009);reduce the patient’s total score of symptoms and signs(SMD=-1.21,95%CI[-1.82,-0.61],P<0.0001)And TCM symptom scores(SMD=-0.98,95%CI[-1.28,-0.68],P<0.00001);superior to the control group in improving patients'nasal congestion,nasal itching,and turbinate/nasal mucosa enlargement,in improving runny nose There is no obvious advantage compared with the control group in terms of sneezing symptoms;in terms of safety,there are fewer mild adverse reactions in the treatment group(RD=-0.05,95%CI[-0.09,-0.00],P=0.04).Conclusion:Compared with H1 antihistamine,Peitu Shengjin prescription can improve clinical efficacy,improve patients'symptoms and signs and TCM symptoms,regulate immune function,and is not easy to relapse and has good safety.展开更多
目的:本研究旨在客观评价温阳培土汤对膜性肾病患者的疗效性及安全性。方法:本研究采用治疗前后自身对照临床研究方法。61例膜性肾病患者在基础治疗之上,予自拟温阳培土汤口服,观察比较患者治疗前后中医症候积分及实验室理化指标改善情...目的:本研究旨在客观评价温阳培土汤对膜性肾病患者的疗效性及安全性。方法:本研究采用治疗前后自身对照临床研究方法。61例膜性肾病患者在基础治疗之上,予自拟温阳培土汤口服,观察比较患者治疗前后中医症候积分及实验室理化指标改善情况。结果:经治疗24周,临床控制9例,显效35例,有效15例,无效2例,总有效率96.72%。中医证候积分较治疗前显著降低,差异具有统计学意义(P<0.05)。患者Alb、BNP、ET-1、24 h UTP、TC、LDL较治疗前均明显改善,差异具有统计学意义(P<0.05)。结论:温阳培土汤对改善患者中医症候,提高血清白蛋白水平,减少尿蛋白定量,改善水肿情况,降低B型钠尿肽及内皮素ET-1水平具有明显疗效。展开更多
基金Research and Development project of"Ten Diseases and ten Drugs"of Beijing Municipal Commission of Science and Technology(No.Z141100002214018)。
文摘Objective:To evaluate the efficacy and safety of Peitu Shengjin prescription versus H1 antihistamine in the treatment of allergic rhinitis.Methods:Electronic searching"China Knowledge Network","Wanfang Database","Vip Database","Chinese Biomedical Literature Database",PubMed,Embase,The Cochrane Library,all published on the prescription of Peitu Shengjin prescription comparison H1 antihistamine In randomized controlled trials(RCTs)of drug treatment of allergic rhinitis,two researchers screened the literature according to the inclusion and exclusion criteria,and conducted Meta-analysis using RevMan5.3 software.Results:A total of 22 studies were involved,involving a total of 1463 subjects,including 822 in the treatment group and 641 in the control group.Meta-analysis results show that compared with oral H1 antihistamines,Peitu Shengjin prescription can improve the total effective rate of allergic rhinitis(RR=1.19,95%CI[1.14,1.24],P<0.00001);reduce recurrence Rate(RR=0.46,95%CI[0.23,0.90],P=0.02);reduce serum IL-6(MD=-17.33,95%CI[-21.96,-12.70],P<0.00001)and serum IL-8(MD=-100.35,95%CI[-175.18,-25.52],P=0.009);reduce the patient’s total score of symptoms and signs(SMD=-1.21,95%CI[-1.82,-0.61],P<0.0001)And TCM symptom scores(SMD=-0.98,95%CI[-1.28,-0.68],P<0.00001);superior to the control group in improving patients'nasal congestion,nasal itching,and turbinate/nasal mucosa enlargement,in improving runny nose There is no obvious advantage compared with the control group in terms of sneezing symptoms;in terms of safety,there are fewer mild adverse reactions in the treatment group(RD=-0.05,95%CI[-0.09,-0.00],P=0.04).Conclusion:Compared with H1 antihistamine,Peitu Shengjin prescription can improve clinical efficacy,improve patients'symptoms and signs and TCM symptoms,regulate immune function,and is not easy to relapse and has good safety.
文摘目的:本研究旨在客观评价温阳培土汤对膜性肾病患者的疗效性及安全性。方法:本研究采用治疗前后自身对照临床研究方法。61例膜性肾病患者在基础治疗之上,予自拟温阳培土汤口服,观察比较患者治疗前后中医症候积分及实验室理化指标改善情况。结果:经治疗24周,临床控制9例,显效35例,有效15例,无效2例,总有效率96.72%。中医证候积分较治疗前显著降低,差异具有统计学意义(P<0.05)。患者Alb、BNP、ET-1、24 h UTP、TC、LDL较治疗前均明显改善,差异具有统计学意义(P<0.05)。结论:温阳培土汤对改善患者中医症候,提高血清白蛋白水平,减少尿蛋白定量,改善水肿情况,降低B型钠尿肽及内皮素ET-1水平具有明显疗效。
